 SAN DIEGO, Sept. 30, 2021 GLOBE NEWSWIRE -- eFFECTOR Therapeutics NASDAQ: EFTR, a leader in the development of selective translation regulator inhibitors STRIs for the treatment of cancer, today announced that eFFECTOR-supported research from Baylor College of Medicine entitled, The RNA helicase EIF4A is a therapeutic vulnerability in triple-negative breast cancer has been accepted as a poster presentation at the upcoming 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 